Carisma Therapeutics at the Evercore ISI HealthCONx Conference
Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, is set to participate in an influential healthcare investment event soon. On this occasion, Steven Kelly, the President and Chief Executive Officer of Carisma, will take part in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. This engaging session is scheduled to take place on Thursday in December.
Focus on Innovative Immunotherapies
Carisma Therapeutics is dedicated to pioneering innovative immunotherapies using their proprietary macrophage and monocyte cell engineering platform. They want to make significant strides in treating cancer and other serious illnesses. The focus is on engineered macrophages and monocytes, which are vital cells in both the innate and adaptive immune systems and instrumental in combating diseases.
Audio Webcast Details
Investors and stakeholders will have the opportunity to listen to an audio webcast of the event. This will be accessible through the Company’s Investor Relations webpage. The webcast will not only provide insights during the conference but will also be archived for listeners who wish to revisit the conversation afterward.
About Carisma Therapeutics Inc.
Carisma is at the forefront of biopharmaceutical innovation, aiming to create transformative therapies that leverage the body’s immune response. Their comprehensive cell therapy platform sets them apart in the competitive biopharmaceutical industry, enabling them to tackle various health challenges by harnessing the immune system more effectively.
Investor Relations and Media Contacts
For those interested in knowing more about Carisma Therapeutics, there are contacts available for further inquiries. Shveta Dighe, the Head of Investor Relations, can be reached for investor-related questions. Media inquiries can be directed to Julia Stern, who is available for interviews and discussions related to the company’s ventures.
Frequently Asked Questions
What is the focus of Carisma Therapeutics?
Carisma Therapeutics focuses on developing innovative immunotherapies utilizing their proprietary macrophage and monocyte cell engineering platform.
Who is participating in the HealthCONx conference?
Steven Kelly, the President and CEO of Carisma Therapeutics, will participate in a fireside chat at the conference.
How can investors access the conference audio?
The audio webcast can be accessed through the Investor Relations section of Carisma's website and will be archived afterward.
What sets Carisma apart in the biopharmaceutical field?
Carisma employs a unique cell therapy platform focusing on engineered macrophages and monocytes, which are crucial in the immune response to treatment.
Who can be contacted for investor inquiries?
Shveta Dighe, the Head of Investor Relations, is available for any investor-related questions.
